8-K filings / November 20, 2026
Biofrontera Inc.: A stock exchange listing notice
Biofrontera Inc. filed a current report (Form 8-K) with the SEC on November 20, 2026. It reports a stock exchange listing notice.
Item 3.01
Stock exchange listing notice
-
Exchange
Nasdaq
From the filing
Source
“On November 16, 2026, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days.”
Read by code from this sentence of the filing. -
What it says
The company does not meet a listing rule
From the filing
Source
“On November 16, 2026, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days.”
Read by code from this sentence of the filing. -
Rule cited
Nasdaq Listing Rule 5550(a)(2)
From the filing
Source
“On November 16, 2026, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days.”
Read by code from this sentence of the filing. -
Notice date
November 16, 2026
From the filing
Source
“On November 16, 2026, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days.”
Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.